ARVINAS, INC. (ARVN) Operating Margin
- Operating margin · 12 months: Value -5.72%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -5.72% | Operating income / revenue. Period ending 2026-06-30. $-18.10M ÷ $316.70M × 100 ≈ -5.72% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -18.10M USD | Operating Income (Loss) |
| Revenue | 316.70M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 238.80M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-18.10M | $316.70M | (m) | $238.80M | (m) | -5.72% |
| 2026-03-31 | $-253.70M | $89.40M | (m) | $254.70M | (m) | -283.78% |
| 2025-12-31 | $-118.50M | $262.60M | (m) | $285.20M | (m) | -45.13% |
| 2025-09-30 | $-102.10M | $312.30M | (m) | $307.40M | (m) | -32.69% |
| 2025-06-30 | $-118.50M | $372.80M | (m) | $329.60M | (m) | -31.79% |
| 2025-03-31 | $-95.50M | $426.90M | (m) | $354.70M | (m) | -22.37% |
| 2024-12-31 | $-250.20M | $263.40M | (m) | $348.20M | (m) | -94.99% |
| 2024-09-30 | $-357.30M | $161.10M | (m) | $360.10M | (m) | -221.79% |
| 2024-06-30 | $-371.00M | $93.30M | (m) | $359.10M | (m) | -397.64% |
| 2024-03-31 | $-397.10M | $71.30M | (m) | $368.70M | (m) | -556.94% |
| 2023-12-31 | $-401.50M | $78.50M | (m) | $379.70M | (m) | -511.46% |
| 2023-09-30 | $-311.80M | $159.40M | (m) | $382.80M | (m) | -195.61% |
| 2023-06-30 | $-302.10M | $158.10M | (m) | $374.40M | (m) | -191.08% |
| 2023-03-31 | $-293.20M | $137.40M | (m) | $346.30M | (m) | -213.39% |
| 2022-12-31 | $-263.20M | $131.40M | (m) | $315.00M | (m) | -200.30% |
| 2022-09-30 | $-249.80M | $112.20M | (m) | $278.60M | (m) | -222.64% |
| 2022-06-30 | $-230.00M | $91.10M | (m) | $241.70M | (m) | -252.47% |
| 2022-03-31 | $-213.60M | $65.40M | (m) | $209.50M | (m) | -326.61% |
| 2021-12-31 | $-195.30M | $46.70M | (m) | $180.40M | (m) | -418.20% |
| 2021-09-30 | $-184.07M | $22.60M | (m) | $151.68M | (m) | -814.46% |
| 2021-06-30 | $-168.49M | $20.90M | (m) | $141.09M | (m) | -806.15% |
| 2021-03-31 | $-143.09M | $21.10M | (m) | $121.50M | (m) | -678.16% |
| 2020-12-31 | $-124.86M | $21.80M | (m) | $108.36M | (m) | -572.74% |
| 2020-09-30 | $-104.43M | $24.40M | (m) | $95.57M | (m) | -428.01% |
| 2020-06-30 | $-67.18M | $22.30M | (m) | $82.15M | (m) | -301.26% |
| 2020-03-31 | $-59.12M | $20.50M | (m) | $74.73M | (m) | -288.40% |
| 2019-12-31 | $-51.52M | $18.30M | (m) | $67.19M | (m) | -281.55% |
| 2019-09-30 | $-45.68M | $16.80M | (m) | $61.34M | (m) | -271.89% |
| 2019-06-30 | $-65.24M | $14.79M | (m) | $57.90M | (m) | -441.08% |
| 2019-03-31 | $-55.33M | $14.19M | (m) | $52.24M | (m) | -389.92% |
| 2018-12-31 | $-43.80M | $14.30M | (m) | $45.19M | (m) | -306.31% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-24.52M | $11.75M | (m) | $31.39M | (m) | -208.67% |
| 2018-03-31 | $-22.73M | $10.02M | (m) | $28.88M | (m) | -226.83% |
| 2017-12-31 | $-24.76M | $7.58M | (m) | $28.79M | (m) | -326.70% |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |